Retinalamin

Retinalamin Overview

Retinalamin is a polypeptide bioregulator extracted from cattle retina tissue, consisting of a complex of naturally occurring peptides. It is described as neuroprotective and retinoprotective, working by stimulating tissue-specific proliferation of retinal and pigment epithelial cells, modulating neurotrophic factors, and protecting retinal cells from apoptosis. It is used in ophthalmology mainly for glaucomatous optic neuropathy, diabetic retinopathy, retinal abiotrophy, and photochemical retinal damage. As a peptide, it requires reconstitution, with purity and storage conditions affecting quality.

Editorial Verdict

Retinalamin has more human trial data behind it than most peptides, but nearly all of it comes out of Russian ophthalmology practice, where the product is manufactured and routinely used. That concentration of evidence in a single region, with limited independent Western replication, is worth keeping in mind even though the published results are largely positive.

Evidence Quality

We assign a research grade of A+. The grade rests on 24 peer-reviewed studies: 10 RCTs, 7 observational studies, 2 animal studies, 3 in vitro studies, and 1 review. Of 24 classified findings, 20 were supportive, 2 mixed, and 2 null. The human base includes 10 RCTs, which is unusually strong for a tissue-extract bioregulator.

What the Research Shows

In a rabbit model of photochemical retinal damage, parabulbar Retinalamin produced functional and structural protection, with the best results when treatment began early. An observational study in advanced primary open-angle glaucoma found that 5 mg intramuscular injections every 3 months improved structural and functional measures over two years. A comparison across 498 glaucoma patients reported intramuscular Retinalamin raised retinal sensitivity by 122 units after 3 months, holding at 6 months. In vitro work showed it stimulates proliferation of retinal and pigment epithelial cells. Studies in diabetic retinopathy patients showed improvements in electroretinography and, in 56 patients, in ganglion cell complex thickness on OCT. In 23 glaucoma patients, ten 5 mg injections modulated BDNF and NSE levels. A randomized study of 180 patients (355 eyes) showed improved visual acuity and retinal sensitivity maintained over 12 months. In 33 children aged 4-7 with retinal abiotrophy, treatment stabilized progression in every case, improved acuity in 82% of patients, and enhanced electroretinography in 37% over 18 months. A cell-culture study using mouse retinal ganglion cells supported potential for glaucomatous optic neuropathy.

Dosage

The standard course is 5 mg intramuscularly once daily for 10 days, repeated every 3-6 months for chronic conditions. Parabulbar injection around the eye uses 0.25-5 mg per dose in courses of about 10 injections. Quarterly courses appear more effective than semi-annual for advanced glaucoma, and a complete course generally totals 50 mg regardless of route.

Who Should Be Cautious

The safety record looks favorable: minimal to no adverse effects across hundreds of patients, only the usual injection-site discomfort, no reports of significant systemic toxicity, and continued safety in studies up to 2 years.

Availability

Retinalamin is sold mainly in Russia and former Soviet countries as a pharmaceutical made by Geropharm LLC. It is not an over-the-counter supplement; it requires medical supervision and professional administration, and availability in Western markets is limited.

Bottom Line

The human data are unusually deep and largely positive for a peptide of this type, but the evidence is heavily concentrated in one region and would benefit from broader independent confirmation.